| [[null, "<p>\u6b22\u8fce\u4f7f\u7528 \u5f20\u5e73\u7684\u4e13\u5c5e\u77e5\u8bc6\u5e93\uff01</p></p>\n<p>\u8bf7\u5728\u53f3\u4fa7\u5207\u6362\u6a21\u5f0f\uff0c\u76ee\u524d\u652f\u6301\u76f4\u63a5\u4e0e LLM \u6a21\u578b\u5bf9\u8bdd\u6216\u57fa\u4e8e\u672c\u5730\u77e5\u8bc6\u5e93\u95ee\u7b54\u3002\n\u77e5\u8bc6\u5e93\u95ee\u7b54\u6a21\u5f0f\uff0c\u9009\u62e9\u77e5\u8bc6\u5e93\u540d\u79f0\u540e\uff0c\u5373\u53ef\u5f00\u59cb\u95ee\u7b54\uff0c\u5982\u6709\u9700\u8981\u53ef\u4ee5\u4e0a\u4f20\u6587\u4ef6/\u6587\u4ef6\u5939\u81f3\u77e5\u8bc6\u5e93\u3002\n\u77e5\u8bc6\u5e93\u6682\u4e0d\u652f\u6301\u6587\u4ef6\u5220\u9664\u3002"], [null, "\u6a21\u578b\u5df2\u6210\u529f\u52a0\u8f7d\uff0c\u53ef\u4ee5\u5f00\u59cb\u5bf9\u8bdd\uff0c\u6216\u4ece\u53f3\u4fa7\u9009\u62e9\u6a21\u5f0f\u540e\u5f00\u59cb\u5bf9\u8bdd"], [null, "\u5df2\u52a0\u8f7d\u77e5\u8bc6\u5e93tumor-diag\uff0c\u8bf7\u5f00\u59cb\u63d0\u95ee"], ["introduce Clinical Practice Guidelines", "<p>\u6839\u636e\u6240\u63d0\u4f9b\u7684\u5df2\u77e5\u4fe1\u606f\uff0c\u4e34\u5e8a\u5b9e\u8df5\u6307\u5357\uff08Clinical Practice Guidelines\uff09\u662f\u5728\u6210\u4eba\u764c\u75c7\u6cbb\u7597\u671f\u95f4\u5bf9\u5e78\u5b58\u8005\u8fdb\u884c\u4e34\u5e8a\u5b9e\u8df5\u6307\u5bfc\u7684\u6807\u51c6\u5316\u6307\u5bfc\u6587\u4ef6\u3002\u8fd9\u4e9b\u6307\u5357\u901a\u5e38\u5305\u62ec\u80bf\u7624\u5b66\u3001\u4e34\u5e8a\u5b9e\u8df5\u3001\u80bf\u7624\u6cbb\u7597\u548c\u968f\u8bbf\u7b49\u65b9\u9762\u7684\u4e3b\u9898\uff0c\u65e8\u5728\u4e3a\u533b\u751f\u63d0\u4f9b\u660e\u786e\u7684\u6307\u5bfc\uff0c\u4ee5\u4fbf\u4e3a\u60a3\u8005\u63d0\u4f9b\u6700\u4f73\u7684\u6cbb\u7597\u548c\u62a4\u7406\u3002</p>\n<p>\u4f8b\u5982\uff0c\u7f8e\u56fd\u56fd\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u5236\u5b9a\u7684\u300a\u5c40\u90e8\u7ed3\u80a0\u764c\uff1aESMO\u4e34\u5e8a\u5b9e\u8df5\u6307\u5357 for \u8bca\u65ad\u3001\u6cbb\u7597\u548c\u968f\u8bbf\u300b\u662f\u4e00\u7bc7\u5173\u4e8e\u7ed3\u80a0\u764c\u4e34\u5e8a\u5b9e\u8df5\u7684\u6307\u5357\uff0c\u6db5\u76d6\u4e86\u8bca\u65ad\u3001\u6cbb\u7597\u548c\u968f\u8bbf\u7b49\u65b9\u9762\u7684\u4e3b\u9898\uff0c\u4e3a\u533b\u751f\u63d0\u4f9b\u4e86\u4e13\u4e1a\u7684\u6307\u5bfc\u3002</p>\n<p>\u6b64\u5916\uff0c\u4e00\u4e9b\u5b66\u672f\u671f\u520a\uff0c\u5982\u300aAnn Oncol\u300b\u548c\u300aN Engl J Med\u300b\uff0c\u4e5f\u53d1\u8868\u4e86\u5173\u4e8e\u764c\u75c7\u4e34\u5e8a\u5b9e\u8df5\u6307\u5357\u7684\u7814\u7a76\u8bba\u6587\uff0c\u8fd9\u4e9b\u7814\u7a76\u8bba\u6587\u65e8\u5728\u63a2\u8ba8\u80bf\u7624\u5b66\u3001\u4e34\u5e8a\u5b9e\u8df5\u548c\u80bf\u7624\u6cbb\u7597\u7b49\u65b9\u9762\u7684\u95ee\u9898\uff0c\u5e76\u4e3a\u533b\u751f\u63d0\u4f9b\u6709\u4ef7\u503c\u7684\u53c2\u8003\u3002</p>\n<details> <summary>\u51fa\u5904 [1] ColonCancer_2023.V2_EN.pdf</summary>\n Results were confined to the following article types: Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Practice Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.\n</details><details> <summary>\u51fa\u5904 [2] ColonCancer_2023.V2_EN.pdf</summary>\nwho work with survivors of adult-onset cancer in the post-treatment period, including those in specialty cancer survivor clinics and primary care practices. The NCCN Guidelines for Survivorship include many topics with potential relevance \n</details><details> <summary>\u51fa\u5904 [3] ColonCancer_2023.V2_EN.pdf</summary>\nncbi. nlm. nih. gov/pubmed/36646802. 360. Argiles G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31:1291-1305. Available at: https://www. ncbi. nlm. nih.\n</details><details> <summary>\u51fa\u5904 [4] ColonCancer_2023.V2_EN.pdf</summary>\nncbi. nlm. nih. gov/pubmed/17060676. 1046. Pfister DG, Benson AB, 3rd, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004; 350:2375-2382. Available at: http://www. ncbi. nlm. nih.\n</details>"], ["introduce NCCN", "<p>NCCN\uff08National Comprehensive Cancer Network\uff09\u662f\u4e00\u4e2a\u81f4\u529b\u4e8e\u4e3a\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u6700\u4f73\u62a4\u7406\u548c\u6cbb\u7597\u65b9\u6848\u7684\u56fd\u9645\u7ec4\u7ec7\u3002\u8be5\u7ec4\u7ec7\u6210\u7acb\u4e8e1990\u5e74\uff0c\u603b\u90e8\u4f4d\u4e8e\u7f8e\u56fd\u9a6c\u8428\u8bf8\u585e\u5dde\u5251\u6865\u5e02\u3002NCCN\u901a\u8fc7\u5236\u5b9a\u4e34\u5e8a\u5b9e\u8df5\u6307\u5357\uff0c\u4e3a\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u660e\u786e\u7684\u6cbb\u7597\u5efa\u8bae\uff0c\u5e2e\u52a9\u533b\u751f\u66f4\u597d\u5730\u4e3a\u60a3\u8005\u63d0\u4f9b\u62a4\u7406\u3002</p>\n<p>NCCN\u6307\u5357\u8986\u76d6\u4e86\u5404\u79cd\u764c\u75c7\u7c7b\u578b\uff0c\u5305\u62ec\u80ba\u764c\u3001\u4e73\u817a\u764c\u3001\u524d\u5217\u817a\u764c\u3001\u7ed3\u80a0\u764c\u7b49\u3002\u9488\u5bf9\u6bcf\u79cd\u764c\u75c7\u7c7b\u578b\uff0cNCCN\u6307\u5357\u90fd\u63d0\u4f9b\u4e86\u80bf\u7624\u5b66\u3001\u4e34\u5e8a\u5b9e\u8df5\u3001\u80bf\u7624\u6cbb\u7597\u548c\u968f\u8bbf\u7b49\u65b9\u9762\u7684\u4e3b\u9898\uff0c\u65e8\u5728\u4e3a\u533b\u751f\u63d0\u4f9b\u660e\u786e\u7684\u6307\u5bfc\u3002</p>\n<p>NCCN\u6307\u5357\u8fd8\u7279\u522b\u5173\u6ce8\u60a3\u8005\u7684\u9700\u6c42\u548c\u5fc3\u7406\u5065\u5eb7\uff0c\u63d0\u4f9b\u5173\u4e8e\u75bc\u75db\u7ba1\u7406\u3001\u60a3\u8005\u53c2\u4e0e\u548c\u5b89\u5b81\u7597\u62a4\u7b49\u65b9\u9762\u7684\u5efa\u8bae\u3002\u8fd9\u4e9b\u6307\u5357\u65e8\u5728\u63d0\u9ad8\u764c\u75c7\u60a3\u8005\u7684\u751f\u5b58\u7387\u548c\u751f\u6d3b\u8d28\u91cf\u3002</p>\n<p>\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0cNCCN\u5728\u80ba\u764c\u6cbb\u7597\u65b9\u9762\u5177\u6709\u5f88\u9ad8\u7684\u6743\u5a01\u6027\u3002\u6839\u636eNCCN\u6307\u5357\uff0c\u643a\u5e26EGFR\u3001ALK\u9a71\u52a8\u7a81\u53d8\u7684\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\u4e0d\u592a\u53ef\u80fd\u4eceICIs\uff08\u514d\u75ab\u68c0\u67e5\u70b9\uff09\u6cbb\u7597\u4e2d\u83b7\u76ca\u3002\u5bf9\u4e8e\u643a\u5e26MET ex14\u8df3\u8bfb\u7a81\u53d8\u7684\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\uff0c\u5c3d\u7ba1PD-L1\u8868\u8fbe\u8f83\u9ad8\uff0c\u4f46ICIs\u7684\u53cd\u5e94\u7387\u4ecd\u8f83\u4f4e\uff0c\u7ea6\u4e3a16%\u3002</p>\n<p>\u603b\u4e4b\uff0cNCCN\u662f\u4e00\u4e2a\u4e3a\u764c\u75c7\u60a3\u8005\u63d0\u4f9b\u6743\u5a01\u6cbb\u7597\u548c\u62a4\u7406\u65b9\u6848\u7684\u56fd\u9645\u7ec4\u7ec7\uff0c\u5176\u6307\u5357\u5728\u80bf\u7624\u5b66\u3001\u4e34\u5e8a\u5b9e\u8df5\u548c\u60a3\u8005\u9700\u6c42\u65b9\u9762\u63d0\u4f9b\u4e86\u5168\u9762\u7684\u6307\u5bfc\u3002</p>\n<details> <summary>\u51fa\u5904 [1] xx_ZL0123936.pdf</summary>\n\u68c0\u6d4b\u610f\u4e49 \u3010\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u3011 ALK \u8d1f\u76f8\u5173 \u672a\u89c1\u76f8\u5173\u53d8\u5f02 - - \u975e\u5c0f\u7ec6\u80de\u80ba\u764c NCCN \u6307\u5357\u4e2d\u63d0\u53ca\uff1a\u591a\u9879\u7814\u7a76\u8868\u660e\u643a\u5e26 EGFR\u3001ALK \u9a71\u52a8\u7a81\u53d8\u7684\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\u4e0d\u592a\u53ef\u80fd\u4ece ICIs \u6cbb\u7597\u4e2d\u83b7\u76ca\uff08PMID\uff1a31125062\u300129874546\uff09\u3002 EGFR \u8d1f\u76f8\u5173 \u672a\u89c1\u76f8\u5173\u53d8\u5f02 - - MET \u8d1f\u76f8\u5173 \u672a\u89c1\u76f8\u5173\u53d8\u5f02 - - \u975e\u5c0f\u7ec6\u80de\u80ba\u764c NCCN \u6307\u5357\u4e2d\u6307\u51fa\uff0c \u643a\u5e26 MET ex14 \u8df3 \u8bfb\u7a81\u53d8\u7684\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\u5bf9 ICIs \u7684\u53cd\u5e94\u7387\u8f83\u4f4e\u7ea6\u4e3a 16%\uff0c \u5c3d\u7ba1\u8fd9\u4e9b\u60a3\u8005 PD-L1 \u9ad8\u8868\u8fbe\u3002\n</details><details> <summary>\u51fa\u5904 [2] ColonCancer_2023.V2_EN.pdf</summary>\nVersion 2. 2023, 04/25/23 \u00a9 2023 National Comprehensive Cancer Network\u00ae (NCCN\u00ae), All rights reserved. NCCN Guidelines\u00ae and this illustration \n</details><details> <summary>\u51fa\u5904 [3] ColonCancer_2023.V2_EN.pdf</summary>\n MS, ASCP Katie Stehman, MMS, PA-C NCCN Guidelines Version 2. 2023 Colon Cancer Version 2. 2023, 04/25/23 \u00a9 2023 National Comprehensive Cancer Network\u00ae (NCCN\u00ae), All rights reserved. NCCN Guidelines\u00ae and this illustration may not be reproduced \n</details><details> <summary>\u51fa\u5904 [4] ColonCancer_2023.V2_EN.pdf</summary>\na health care provider specializing in ostomy care (ie, ostomy nurse) \u0017Screen for distress around body changes (NCCN Guidelines for Distress Management) and precautions around involvement with physical activity (see page SPA-C in the NCCN Guidelines \n</details><details> <summary>\u51fa\u5904 [5] ColonCancer_2023.V2_EN.pdf</summary>\n5 This Discussion summarizes the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Colon Cancer. These guidelines begin with the clinical presentation of \n</details>"], ["introduce NCCN Clinical Practice Guidelines of colon cancer.", "<p>NCCN\u4e34\u5e8a\u5b9e\u8df5\u6307\u5357\uff08NCCN Guidelines\u00ae\uff09\u662fNational Comprehensive Cancer Network\uff08NCCN\uff09\u4e3a\u6cbb\u7597\u5927\u80a0\u764c\u63d0\u4f9b\u6307\u5bfc\u7684\u4e34\u5e8a\u5b9e\u8df5\u6307\u5357\u3002\u8fd9\u4e9b\u6307\u5357\u6db5\u76d6\u4e86\u4ece\u8bca\u65ad\u3001\u6cbb\u7597\u5230\u968f\u8bbf\u7684\u5404\u4e2a\u65b9\u9762\uff0c\u65e8\u5728\u4e3a\u533b\u751f\u63d0\u4f9b\u660e\u786e\u7684\u6307\u5bfc\u3002NCCN\u4e34\u5e8a\u5b9e\u8df5\u6307\u5357\u5305\u62ec\u591a\u4e2a\u90e8\u5206\uff0c\u5982\u80bf\u7624\u5b66\u3001\u4e34\u5e8a\u5b9e\u8df5\u3001\u80bf\u7624\u6cbb\u7597\u548c\u968f\u8bbf\u7b49\u3002\u5176\u4e2d\uff0c\u5bf9\u4e8e\u5e26\u6709EGFR\u3001ALK\u9a71\u52a8\u7a81\u53d8\u7684\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\uff0cNCCN\u6307\u5357\u4e2d\u6307\u51faICIs\uff08\u514d\u75ab\u68c0\u67e5\u70b9\uff09\u6cbb\u7597\u5e76\u4e0d\u9002\u7528\u4e8e\u8fd9\u4e9b\u60a3\u8005\u3002\u5bf9\u4e8e\u643a\u5e26MET ex14\u8df3\u8bfb\u7a81\u53d8\u7684\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u60a3\u8005\uff0c\u5c3d\u7ba1PD-L1\u8868\u8fbe\u8f83\u9ad8\uff0c\u4f46ICIs\u7684\u53cd\u5e94\u7387\u4ecd\u8f83\u4f4e\uff0c\u7ea6\u4e3a16%\u3002\u6b64\u5916\uff0cNCCN\u6307\u5357\u8fd8\u7279\u522b\u5173\u6ce8\u60a3\u8005\u7684\u9700\u6c42\u548c\u5fc3\u7406\u5065\u5eb7\uff0c\u63d0\u4f9b\u5173\u4e8e\u75bc\u75db\u7ba1\u7406\u3001\u60a3\u8005\u53c2\u4e0e\u548c\u5b89\u5b81\u7597\u62a4\u7b49\u65b9\u9762\u7684\u5efa\u8bae\u3002</p>\n<details> <summary>\u51fa\u5904 [1] ColonCancer_2023.V2_EN.pdf</summary>\nwritten permission of NCCN. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Colon Cancer Version 2. 2023 \u2014 April 25, 2023 Continue NCCN. org NCCN Guidelines for Patients\u00ae available at www. nccn. org/patients \n</details><details> <summary>\u51fa\u5904 [2] ColonCancer_2023.V2_EN.pdf</summary>\npatient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. NCCN Guidelines Index Table of Contents Discussion SUBSEQUENT THERAPYc, o, p Previous oxaliplatin- based therapy without irinotecan CONTINUUM OF \n</details><details> <summary>\u51fa\u5904 [3] ColonCancer_2023.V2_EN.pdf</summary>\npatient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. NCCN Guidelines Index Table of Contents Discussion SUBSEQUENT THERAPYc, o, p Previous irinotecan- based therapy without oxaliplatin CONTINUUM OF \n</details><details> <summary>\u51fa\u5904 [4] ColonCancer_2023.V2_EN.pdf</summary>\nis in a clinical trial. Participation in clinical trials is especially encouraged. NCCN Guidelines Index Table of Contents Discussion SUBSEQUENT THERAPYc, o, p CONTINUUM OF CARE - SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASEa, b, n FOLFOXd or \n</details><details> <summary>\u51fa\u5904 [5] ColonCancer_2023.V2_EN.pdf</summary>\n.. .. .. MS-84 This discussion corresponds to the NCCN Guidelines for Colon Cancer. Last updated April 25, 2023. National Comprehensive NCCN Cancer Network? Version 2.\n</details>"], ["introduce col-1", "Col-1\u662f\u4e00\u79cd\u80a0\u9053\u80bf\u7624\uff0c\u4e5f\u79f0\u4e3a\u7ed3\u80a0\u764c\u3002\u5b83\u901a\u5e38\u751f\u957f\u5728\u7ed3\u80a0\u58c1\u4e0a\uff0c\u4f46\u4e5f\u6709\u53ef\u80fd\u6269\u6563\u5230\u7cfb\u819c\u6216\u7cfb\u819c\u6839\u90e8\u3002\u7ed3\u80a0\u764c\u662f\u5e38\u89c1\u7684\u764c\u75c7\u4e4b\u4e00\uff0c\u4e25\u91cd\u5a01\u80c1\u4eba\u7c7b\u5065\u5eb7\u3002\u6839\u636e\u7edf\u8ba1\uff0c\u7ed3\u80a0\u764c\u5728\u5317\u7f8e\u5730\u533a\u7684\u53d1\u75c5\u7387\u4e3a22,100\u4eba/\u5e74\uff0c\u5c45\u764c\u75c7\u6b7b\u4ea1\u539f\u56e0\u7b2c\u4e8c\u4f4d\u3002\u6cbb\u7597\u7ed3\u80a0\u764c\u7684\u65b9\u6cd5\u5305\u62ec\u624b\u672f\u3001\u653e\u7597\u548c\u5316\u7597\u7b49\u3002\u8fd1\u5e74\u6765\uff0c\u7814\u7a76\u4eba\u5458\u53d1\u73b0\u7ed3\u80a0\u764c\u4e0e\u591a\u79cd\u57fa\u56e0\u548c\u73af\u5883\u56e0\u7d20\u6709\u5173\uff0c\u5982APC\u57fa\u56e0\u7a81\u53d8\u3001\u708e\u75c7\u53cd\u5e94\u548c\u80a0\u9053\u5fae\u751f\u6001\u7b49\u3002\n\n<details> <summary>\u51fa\u5904 [1] ColonCancer_2023.V2_EN.pdf</summary>\nUpdates Clinical Presentations and Primary Treatment: \u2022 Pedunculated or Sessile Polyp (Adenoma) with Invasive Cancer (COL-1) \u2022 Workup for Colon Cancer Appropriate for Resection (Non-metastatic)/Suspected or Proven Metastatic Adenocarcinoma (COL-2) \u2022 \n</details><details> <summary>\u51fa\u5904 [2] ColonCancer_2023.V2_EN.pdf</summary>\nUpdates Clinical Presentations and Primary Treatment: \u2022 Pedunculated or Sessile Polyp (Adenoma) with Invasive Cancer (COL-1) \u2022 Workup for Colon Cancer Appropriate for Resection (Non-metastatic)/Suspected or Proven Metastatic Adenocarcinoma (COL-2) \u2022 \n</details><details> <summary>\u51fa\u5904 [3] ColonCancer_2023.V2_EN.pdf</summary>\nthe header on pages COL-3 through COL-11 \u2022 Terminologies modified to advance the goals of equity, inclusion, and representation. COL-1 \u2022 Workup \u0017Bullet 3 revised: Marking of cancerous polyp site (at time of colonoscopy or within 2 weeks if \n</details><details> <summary>\u51fa\u5904 [4] ColonCancer_2023.V2_EN.pdf</summary>\n NCCN Guidelines Index Table of Contents Discussion Pedunculated or sessile polyp (adenoma) with invasive cancer COL-1 a All patients with colon cancer should be counseled for family history and considered for risk assessment.\n</details>"]] |